Get the Stockscreener App
33.56
2.63%
0.86
After Hours:
33.99
0.43
+1.28%
Edgewise Therapeutics Inc stock is traded at $33.56, with a volume of 1.30M.
It is up +2.63% in the last 24 hours and up +6.27% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
See More
Previous Close:
$32.70
Open:
$32.65
24h Volume:
1.30M
Relative Volume:
1.29
Market Cap:
$3.61B
Revenue:
-
Net Income/Loss:
$-167.80M
P/E Ratio:
-20.56
EPS:
-1.6323
Net Cash Flow:
$-144.07M
1W Performance:
+6.78%
1M Performance:
+6.27%
6M Performance:
+31.50%
1Y Performance:
+136.17%
1-Day Range:
$31.75
$33.76
1-Week Range:
$31.75
$33.76
52-Week Range:
$12.15
$39.96
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
33.56 | 3.52B | 0 | -167.80M | -144.07M | -1.6323 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Why (EWTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $52 - Moomoo
EWTX Stock Chart | EDGEWISE THERAPEUTICS INC (NASDAQ:EWTX) - ChartMill
Edgewise Therapeutics, Inc.Common Stock (NQ: EWTX - The Chronicle-Journal
Janus Henderson (EWTX) reports 5.5% ownership — 5.9M shares disclosed - Stock Titan
Understanding Momentum Shifts in (EWTX) - Stock Traders Daily
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo Finance
Muscle disease drug developer heads to RBC healthcare event May 20 - Stock Titan
TradingKey - TradingKey
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026 - Yahoo Finance
Edgewise Therapeutics' Update for EDG-7500 Could Boost Shares, RBC Says - Moomoo
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50 - Moomoo
H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Edgewise boosts R&D spending as drug trials bear promising results - BizWest
Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Edgewise Therapeutics Shares Decline Amid Wider Q1 Loss - Moomoo
Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Do Edgewise Therapeutics' (EWTX) New Stock Grants Clarify or Complicate Its Pipeline Execution Story? - Yahoo Finance
Earnings Flash (EWTX) Edgewise Therapeutics Posts Q1 Net Loss $0.46 a Share, vs. FactSet Est of $0.49 Net Loss a Share - marketscreener.com
Edgewise Therapeutics (NASDAQ:EWTX) Beats Q1 Estimates as Long-Term Data Strengthens Case for Sevasemten - ChartMill
Edgewise Therapeutics (NASDAQ: EWTX) posts Q1 2026 net loss of $49M - Stock Titan
EDGEWISE THERAPEUTICS ($EWTX) Releases Q1 2026 Earnings - Quiver Quantitative
Edgewise Therapeutics Q1 net loss widens on higher R&D costs - TradingView
Edgewise Therapeutics 1Q 2026: Net income $(49.0M), EPS $(0.46) — 10-Q Summary - TradingView
Edgewise Therapeutics (NASDAQ: EWTX) reports Q1 2026 loss, $499.6M cash - Stock Titan
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications - PR Newswire
Edgewise Therapeutics earnings on deck as losses widen By Investing.com - Investing.com Australia
Edgewise Therapeutics earnings on deck as losses widen - Investing.com
Truist Securities Adjusts Price Target on Edgewise Therapeutics to $52 From $46, Maintains Buy Rating - marketscreener.com
Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary - GlobeNewswire Inc.
Edgewise Therapeutics stock hits 52-week high at $39.96 By Investing.com - Investing.com Australia
Edgewise Therapeutics (EWTX) Explodes 23% on Pipeline Momentum and Strong Biotech Sentiment - International Business Times Australia
Edgewise Therapeutics CMO Donovan sells $2.09 million of stock - Investing.com India
Edgewise Therapeutics Stock Climbs On Catalyst-Rich Pipeline - timothysykes.com
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
50,000-share sale notice for EWTX (NASDAQ: EWTX) - Stock Titan
Edgewise Therapeutics CMO Donovan sells $2.09 million of stock By Investing.com - Investing.com South Africa
Raymond James Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Edgewise Therapeutics Cmo Sold Shares Worth Over $2.0M - TradingView
Edgewise Therapeutics (EWTX) CMO sells 55,230 shares under 10b5-1 plan - Stock Titan
Cytokinetics metrics satisfy in nHCM phase III - BioWorld News
Edgewise Therapeutics stock hits 52-week high at $39.96 - Investing.com
Edgewise Therapeutics reports inducement grants as permitted by the Nasdaq Listing Rules - marketscreener.com
Edgewise Therapeutics Reports Inducement Grants As Permitted By The Nasdaq Listing Rules - TradingView
9 new Edgewise hires receive stock options for 266,000 shares - Stock Titan
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edgewise Therapeutics Inc Stock (EWTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Donovan Joanne M. | CMO |
May 05 '26 |
Option Exercise |
7.08 |
50,000 |
354,000 |
54,367 |
| Donovan Joanne M. | CMO |
May 05 '26 |
Sale |
38.57 |
50,000 |
1,928,400 |
4,367 |
| Donovan Joanne M. | CMO |
May 04 '26 |
Sale |
31.29 |
5,230 |
163,663 |
4,367 |
| Donovan Joanne M. | CMO |
Apr 01 '26 |
Option Exercise |
7.08 |
28,662 |
202,927 |
38,259 |
| Donovan Joanne M. | CMO |
Apr 01 '26 |
Sale |
32.31 |
28,662 |
926,095 |
9,597 |
| Donovan Joanne M. | CMO |
Mar 31 '26 |
Option Exercise |
7.08 |
21,338 |
151,073 |
30,935 |
| Donovan Joanne M. | CMO |
Mar 31 '26 |
Sale |
32.12 |
21,338 |
685,308 |
9,597 |
| Donovan Joanne M. | CMO |
Mar 27 '26 |
Sale |
30.98 |
16,358 |
506,735 |
9,597 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):